Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.
Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.
https://content.time.com/time/specials/packages/article/0,28804,2019712_2019694_2019588,00.html
Yes, I know. As I mentioned in another reply, I was mentioning it only to give a sense of timeline and hype. Not a justification. Nice gotcha, but misses the broader points.